CURRENT PHARMACEUTICAL LETTERS AND REVIEWS (CPLR)

Available online on http://www.cplr.in/

Review

Current Pharmaceutical Letters and Reviews 2024; 01(01); 25-37

# Embelin as a Promising Therapeutic Agent: Current Advances and Future Perspectives

**Manoj Kumar*, Smriti Gohri, Shadab Ali**

*Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India*

***Abstract:***

*Embelin, which is derived from plants belonging to the genus Embelia, most eminently Embelia ribes Burm. has been respected in conventional medicinal practices for quite a while due to the pharmacological properties that it possesses. These properties are essentially a result of the element hydroxyl benzoquinone that it contains. A lot of interest in its possible therapeutic applications, outstandingly in the treatment of cancer, has been ignited as a result of its recent discovery as a non-peptidic, cell-permeable inhibitor of the X-linked inhibitor of apoptosis protein (XIAP). As a potential anticancer medication, Embelin demonstrates a promising profile by demonstrating a range of anticancer mechanisms across a variety of cancer types. These mechanisms include the acceptance of apoptosis, the arrest of the cell cycle, and autophagy creation. The control of significant sign transduction pathways, like NF-κB, PI3Kinase/AKT, and STAT3, further demonstrates the effectiveness of this compound in preventing the development of several cancer cell lines. The purpose of this extensive literature review is to give a detailed investigation of the anticancer potential of Embelin, explaining its mechanisms of activity and featuring potential clinical uses. Besides the fact that this review features recent advancements, yet it additionally provides clever perspectives into the future trajectory of Embelin-based therapies, thereby pushing for continued research and clinical interpretation in the field of cancer therapeutics. This review draws upon relevant scientific literature from the previous decade that was sourced from a variety of electronic databases.*

***Keywords:*** *Embelin, cancer, bioavailability, toxicity, embelia ribes, Therapeutic Agent, Therapeutic Agent, Current Advances, and Future Perspectives.*

***Received:*** *25-05-2024 /* ***Revised:*** *23-06-2024 /* ***Accepted:*** *03-07-2024*

***Corresponding Author:*** *Manoj Kumar*

***Email:*** *sharmamanoj80572@gmail.com*

***Conflict of interest****: Nil*



## Introduction:

A significant increase in death rates is expected to occur by the year 2040, according to predictions, which indicates that cancer, which is a formidable global health concern, continues to fall short of a sustainable resolution. Given the urgency of the situation, it is very necessary to find a solution that is both all-encompassing and long-lasting in order to combat this specific non-communicable disease [1]. A coordinated effort has been undertaken by governments and associations all over the world in order to achieve this ambition. These efforts have included investments in a variety of project schemes that are targeted at advancing cancer research and treatment therapies [2]. Existing anticancer drugs have a number of limitations, including the imposition of unpleasant side effects and the development of treatment resistance in cancer cells. This is despite the fact that there have been improvements in the knowledge of the mechanisms that cause cancer. Taking into consideration these obstacles, alternative therapies are gaining traction as potentially useful supplementary techniques for the management of cancer conditions [3].

Phytomolecules, which are regular combinations derived from plants, have emerged as prospective prospects for the development of successful anticancer therapeutics [4]. These phytomolecules offer alternatives or supplementary choices to current treatments. Embelin, a benzoquinone that is mostly generated from Embelia ribes Burma, has attracted interest among these phytomolecules due to the several pharmacological qualities that

it possesses, including the potential to inhibit the growth of cancer cells [5].




**Figure 1: plants of Embelia**

Embelin has been shown to have a variety of therapeutic effects, including anticancer activity, in preclinical investigations. It has traditionally been used in Ayurvedic, Siddha, and Unani medicinal formulations for the treatment of a wide range of health disorders. The purpose of this study is to investigate the growing potential of Embelin as a viable therapeutic agent against cancer. Specifically, the research will focus on clarifying its mechanisms of action and addressing crucial issues that influence its clinical translation. The purpose of this study is to increase our understanding of Embelin's function in the ongoing fight against cancer and to prepare the way for future research and therapeutic breakthroughs in this promising field. This will be accomplished by conducting a complete examination of Embelin's anticancer mechanisms and by addressing clinical factors [6].

**Embelin's Ethnobotany:**

In recent years, embelin, a bioactive molecule that has been tracked down in abundance in numerous species of the genus Embelia, especially in Embelia ribes, has attracted a great deal of attention due to the way that it possesses a wide range of pharmacological properties and can possibly be used in therapeutic applications. Embelin, which has the IUPAC name 2,5-dihydroxy-3-undecyl-1,4-benzoquinone, possesses a distinctive chemical structure that includes two carbonyl gatherings, a methine gathering, and two hydroxyl gatherings. Furthermore, it possesses an undecyl alkyl chain, which contributes to its increased lipophilicity and cell permeability. Because of this molecular setup, it can interact with natural systems in an efficient manner, which paves the way for its investigation as a potentially useful therapeutic agent [7].

In the course of research into the pharmacological effects of Embelin, the multifarious nature of the substance was discovered. Embelin has been demonstrated to exhibit significant anticancer, antibacterial, alleviating, and cell-reinforcing properties, according to research. One of the most remarkable characteristics of this substance is its ability to inhibit the NF-κB pathway, which is a crucial signalling pathway that plays a role in irritation, resistance, and the advancement of cancer. As a result of its ability to modify the movement of NF-κB, Embelin demonstrates that it possesses powerful calming effects, which makes it a prospective candidate for the treatment of provocative circumstances such as joint pain and incendiary diseases of the intestine. Moreover, Embelin has exhibited promising anticancer activities by several mechanisms, including enlistment of apoptosis, restriction of cell growth, and suppression of angiogenesis. It is a crucial weapon in the fight against cancer because of its ability to target several pathways that are implicated in the formation and progression of cancer. In addition, the antibacterial movement of Embelin has been explored, and the results have demonstrated that it is effective against a wide variety of pathogens. This indicates that it may have significant applications in the fight against infectious diseases [8].

Embelin's pharmacokinetic profile, which is characterised by its lipophilic nature and cell permeability, promotes its bioavailability and tissue appropriation, further boosting its therapeutic efficacy. Embelin is a molecule that has been shown to have several therapeutic applications. However, in order to fully harness its therapeutic potential, it is necessary to solve a number of difficulties, such as its poor aqueous dissolvability and metabolic unsteadiness. These obstacles could be overcome through the implementation of strategies such as detailed development and prodrug design, which would result in an increase in the therapeutic utility of Embelin. Furthermore, research that focuses on the phytochemical component of Embelia species, particularly E. ribes, has provided vital insights into the factors that influence the concentration of Embelin and other bioactive constituents (also known as "bioactive constituents"). Geographical variants, environmental factors, and extraction techniques all play significant roles in determining the phytochemical profile of Embelia plants, which in turn influences the medicinal qualities of these plants [9].

Embelin has emerged as a potentially useful therapeutic drug, being capable of a wide range of pharmacological activities and having the potential to be used to a variety of medical situations. In order to fully exploit its therapeutic potential and put it into clinical practice, it is necessary to conduct additional research that investigates its mechanisms of activity, pharmacokinetics, plan strategies, and clinical efficacy. Embelin has the potential to become a vital addition to the arsenal of modern medicine if further research and development are conducted on it. It will also provide new opportunities for the creation of innovative therapies [10].

**Phytochemistry Of Embelin and Its Derivatives:**

Embelin, which has a core component of benzoquinone, has recently emerged as a potentially useful therapeutic medication that possesses powerful anticancer movement. As per the discoveries of research on molecular securing and structure-movement relationship, the carbonyl, hydroxyl, and long-chain alkyl gatherings of Embelin assume significant parts in the anticancer activities of the compound. To be more specific, these clusters interact with the peptide backbone and different residues, which ultimately results in the hindrance of p300/CBP associated factor (PCAF) lysine acetyltransferase, an essential enzyme that assumes a part in the progression of cancer [11]. In order to improve the effectiveness of Embelin as an anticancer agent, many structural modifications have been investigated. It has been demonstrated that the alkylation of a single hydroxyl group with derivatives of alkyl, allyl, and benzyl can exert a significant anticancer effect on a variety of cancer cell lines. Additionally, several derivatives, such as 5-O-methyl-Embelin and 5-O-ethyl-Embelin benzoquinone, have shown improved anticancer action when compared to human kidney cell lines, demonstrating that they have the potential to be effective anticancer medicines [12].

It has been demonstrated that the production of Embelin derivatives with specific modifications, such as the 5-(-chloro-4-trifluoromethoxy-phenylamine derivative, has shown promising results in reducing the cell reasonability of melanoma cell lines. XIAP is an essential molecular target that has been implicated in cancer cell endurance and apoptosis avoidance. XIAP has been specifically inhibited as a result of underlying alterations that target the long-chain alkyl gathering of Embelin with mono and biphenyl alkyl substituents. This is an outstanding achievement [13].

The significance of Embelin derivatives in the process of research and development of anticancer medications is highlighted by these discoveries. Researchers anticipate that they will be able to maximize the therapeutic potential of Embelin for the treatment of cancer by developing a better understanding of the structure-movement interactions and investigating the different changes. The development of novel Embelin derivatives has promise for overcoming obstacles, for example, drug resistance and further developing efficacy against a wide variety of cancer types. Likewise, the development of these derivatives holds promise for overcoming challenges [14].

When looking to the future, it is possible that future research initiatives in this subject will focus on further clarifying the molecular pathways that are responsible for the anticancer effects of Embelin and its derivatives. In addition, the efforts that are being made to optimise design tactics, improve pharmacokinetic qualities, and lead preclinical and clinical research are crucial measures that are being taken in order to harness the full therapeutic potential of Embelin as a beneficial anticancer treatment. Taking everything into consideration, the investigation of Embelin and its derivatives constitutes a novel field of research that has significant implications for the treatment of cancer and the creation of medicine [15].




**Figure 2: Structures of anticancer Embelin and its derivatives.**

**Bioavailability And Pharmacokinetics of Embelin:**

Embelin is a promising therapeutic drug that is obtained from regular sources. As a result of its prospective applications in the management of several constant illnesses, the pharmacokinetics of Embelin have been a subject of intense scientific research. For the purpose of improving the therapeutic efficacy and bioavailability of Embelin, it is essential to have a comprehensive understanding of its pharmacokinetic profile. This is especially true when considering the oral administration route, which is a common route for Phyto therapeutic drugs [16].

As per the discoveries of many studies, the oral bioavailability of pure Embelin is relatively low. This can be fundamentally ascribed to the way that it has a weak aqueous dissolvative limit. In their review conducted in 2019, Li et al. observed that the oral bioavailability of Embelin was approximately 30.2 ± 11.9% in male Sprague Dawley mice. This finding features the necessity of developing strategies that can improve its dissolvability and absorption inside the body. It is interesting to note that the invention of a salt type of Embelin with the name potassium embelate resulted in a huge improvement in its oral bioavailability, which reached generally 97%. Because of the greater dissolvability and quick osmosis of potassium embelate, this elevation in bioavailability was ascribed to the way that it led to larger plasma concentrations and improved appointment, remembering aggregation for the brain [17].

The assimilation, circulation, and elimination kinetics of Embelin have been studied in rodents and mice through the use of pharmacokinetic studies, which have provided some insights into these processes. According to Srinivas et al. (2011), the plasma concentration of Embelin in rodents reached its highest point after oral administration. On the other hand, Edderkaoui et al. (2013) discovered that the plasma concentration of athymic nude mice reached its highest point within one hour of oral administration, and then it rapidly decreased over the course of time. These observations point to the fact that there are variations in pharmacokinetic parameters among various creature models and highlight the significance of species-specific considerations in the process of medication development and evaluation [18].

The appropriation of Embelin in several organs, as demonstrated by its collecting in the kidneys, testes, intestines, heart, spleen, and mind, demonstrates its potential for therapeutic applications and targeting of multiple organs at the same time. Embelin was shown to be retained in these organs for an extended period of time, even after 15 days of organisation, as demonstrated by Gupta and Sanyal (1991). This demonstrates that the removal kinetics are sluggish and that there is the potential for sustained therapeutic effects [19].

As per the discoveries of many studies, the oral bioavailability of pure Embelin is relatively low. This can be fundamentally ascribed to the way that it has a weak aqueous dissolvative limit. In their review conducted in 2019, Li et al. observed that the oral bioavailability of Embelin was approximately 30.2 ± 11.9% in male Sprague Dawley mice. This finding features the necessity of developing strategies that can improve its dissolvability and absorption

inside the body. It is interesting to note that the invention of a salt type of Embelin with the name potassium embelate resulted in a huge improvement in its oral bioavailability, which reached generally 97%. Because of the greater dissolvability and quick osmosis of potassium embelate, this elevation in bioavailability was ascribed to the way that it led to larger plasma concentrations and improved appointment, remembering aggregation for the brain [20].

**Embelin's Anticancer Mechanisms: Preclinical Research Provides Evidence:**

Because Embelin has the potential to be used in the treatment of a variety of persistent illnesses, the pharmacokinetics of this promising therapeutic substance that is generated from regular sources have been the topic of intense scientific attention. Embelin's therapeutic efficacy and bioavailability can be significantly improved by gaining a better understanding of its pharmacokinetic profile. This is especially true when considering the oral administration route, which is a common route for phytotherapeutic drugs [21].

Research has shown that pure Embelin has a relatively low oral bioavailability, which can be primarily ascribed to the fact that it has a limited ability to dissolve in water. Embelin's oral bioavailability was approximately 30.2 ± 11.9%, as demonstrated by Li et al. (2019) in male Sprague Dawley mice. This finding highlights the necessity of developing techniques to improve the dissolvability and absorption of Embelin. When potassium embelate, a salt form of embelin, was developed, its oral bioavailability was significantly enhanced, reaching roughly 97%. This is an interesting finding. Because of the greater dissolvability and rapid assimilation of potassium embelate, this elevation in bioavailability was ascribed to the fact that it led to larger plasma concentrations and improved appropriation, remembering aggregation for the mind [22].

A few pieces of information regarding the assimilation, circulation, and elimination kinetics of Embelin have been gleaned from pharmacokinetic studies conducted on rodents and mice. While Edderkaoui et al. (2013) showed maximal plasma concentration in athymic nude mice in the span of one hour following organisation, followed by a rapid fall over time, Srinivas et al. (2011) reported a peak plasma concentration of Embelin in rodents after oral organisation. This discovery was made by Edderkaoui et al. The significance of species-specific considerations in the process of drug development and evaluation is highlighted by these discoveries, which imply varied pharmacokinetic characteristics across a variety of animal models [23].

In addition to its potential for therapeutic applications and multi-organ targeting, the appropriation of Embelin in several organs, as demonstrated by its collection in the kidneys, testes, intestines, heart, and spleen, also demonstrates its potential for use in mind. Gupta and Sanyal (1991) observed that Embelin remained in these organs for an extended period of time, even after 15 days of organisation. This demonstrates that the removal kinetics of Embelin are slow, and it also has the potential to have therapeutic effects that are persistent [24].

When it comes to the therapy of ongoing illnesses, the pharmacokinetics of Embelin are absolutely necessary to exploit its therapeutic potential as a promising medication completely. Researchers might choose to concentrate their efforts in the future on explaining the mechanisms that are responsible for its retention, dispersion, metabolism, and excretion. Moreover, they might investigate novel approaches to enhance its dissolvability, bioavailability, and tissue targeting limit. Embelin can possibly become a valuable therapeutic medication that has expanding uses in the treatment of a variety of constant diseases if these pharmacokinetic problems are addressed [25].

**Table 1: Embelin's Anticancer Effects on Different Types of Cancer: In Vitro Studies.**

| Type of Cancer | Model in vitro using cell lines | Assay | IC50 | Mechanisms/Pathways | Results | Reference |
|---|---|---|---|---|---|---|
| Breast Cancer | MCF-7, MDA-MB-231 | MTT | 15-20 µM | ↓TACE of ↓MMPs ↓hnRNP-K ↓VEGF ↓ | ↓metastasis | Dhanjal (2014) |
| Breast Cancer | CAL-120, EVSAT, MCF-7, MDA-MB-231 | MTT | 25-50 µM | ↓XIAP ↑caspases 3,9 ↑PARP ↑ | ↑apoptosis ↓proliferation | Hussain (2017) |
| Pancreatic Cancer | PC-1, PANC1, MIA PaCa-2, Hs 766T | XTT | - | ↓Akt ↓Shh ↓ | ↓cancer cell growth | Huang (2014) |
| Pancreatic Cancer | MIA PaCa-2, HPAF-II | MTT | - | ↓NF-kβ ↓STAT3 | dose-dependent increase in apoptosis | Edderkaoui (2013) |
| Pancreatic Cancer | Panc 02, Pan 02, H7 | - | - | ↓STAT3 ↑p53 | ↓cell invasion ↓proliferation ↑apoptosis | Peng (2014) |
| Colorectal Cancer | HCT116 | EMSA | - | IL-6/STAT3 ↓IL-6/STAT3 | ↑apoptosis ↓proliferation | Dai (2014) |

| | | | | | | |
|---|---|---|---|---|---|---|
| Bladder Cancer | T24, 5637 | CCK-8 | - | PI3K/Akt | ↓PI3K/Akt ↑apoptosis | Fu (2015) |
| Prostate Cancer | LNCaP, C4-2 | MTT | ~5 µM | ↑caspases 3,9 ↓XIAP | ↓proliferation | Danquah (2009) |
| Prostate Cancer | LNCaP, C4-2 cells | MTT | 6.5 µM | ↓XIAP | ↓proliferation ↓cell growth | Danquah (2012) |
| Prostate Cancer | PC 3 cells | - | - | ↑cell cycle arrest in S-phase | ↓cell growth ↑cancer cell death | Dai (2011) |

**Table 2: In Vivo Studies on the Anticancer Effects of Embelin Using Animal Models Across Various Cancer Types**

| Type of Cancer | In vivo using Animal Models | Doses | Mechanisms/Signaling Pathways | Results | Reference |
|---|---|---|---|---|---|
| Breast Cancer | Nude mice xenograft models of MDA-MB231 cell | 10 mg/kg | ↓XIAP ↓AKT | ↓tumor volume | Hussain (2017) |
| Hepatocarcinoma | Rats Wistar (DENA) | 50 mg/kg | ↑p53 ↑caspases 3, 8 | ↓tumor volume ↓metastatic nodules | Sreepriya and Bali, (2005) |
| Pancreatic Cancer | AsPC-1 xenografts in Balb C nude mice | 40 mg/kg | ↑death receptors DR4, DR5; ↓Shh ↓Akt | ↓AsPC-1 pancreatic tumor growth ↓cancer growth | Huang (2014) |
| | C57BL/6 mice (Ectopic mouse model with H7 or Panc 02 cells) | 50 mg/kg | ↓IL-6-↑STAT3 | ↓metastasis ↓tumor volume | Peng (2014) |
| | Athymic nude mice xenograft models of HPAF-II cells | 75 mg/kg | ↓NF-κB ↓STAT3 phosphorylation and protein expression of its downstream | ↓tumor volume ↓tumor cellularity | Edderkaoui (2013) |
| Colorectal Cancer | C57BL/6 mice (AOM/DSS) | 50 mg/d/kg | ↓IL-6/STAT3 | ↓tumor growth ↓proliferation | Dai (2014) |
| | C57 mice (DMH models) | 100 mg/d/kg | ↑PPARg ↓ NF-kB | ↓tumor incidence ↓tumor multiplicity | Dai (2009) |
| Prostate Cancer | Athymic NCr-nu/nu mice xenograft models of PC-3 cells | 60 mg/kg | ↓XIAP | ↓tumor volume ↓proliferation, ↑apoptosis ↑angiogenesis | Dai (2011) |
| | Athymic nu/nu mice xenograft models of C4-2 cell | 10 mg/kg | ↓XIAP | ↓tumor volume ↓cell growth | Danquah (2012) |
| | Male Balb/c nude mice xenograft models of LNCaP cells | | | | |

**Apoptosis induction:**

Because of its multifarious role in inducing apoptosis, also known as programmed cell death, in several types of cancer, embelin, a distinctive molecule produced from the genus Embelia, has emerged as a potentially useful therapeutic treatment. An abnormal regulation of apoptosis, which is a fundamental process that plays a role in maintaining cellular homeostasis, is an indication that cancer is present. Because it has the ability to cause cancer cells to undergo apoptosis, embelin is a promising candidate for use in cancer treatment procedures [26].

Embelin has been displayed to target both natural and extrinsic mechanisms of apoptosis, as per research studies. The extrinsic pathway, otherwise called the death receptor-mediated pathway, is characterized by the limiting of extracellular ligands like TNF, Fas-L, and TRAIL to death receptors located on the surface of the cell. This limiting ultimately results in the enactment of caspases, which ultimately leads to the death of the cell. It has been demonstrated that Embelin can regulate the extrinsic apoptotic pathway by repressing the expression of genes that are partaking in this route. These genes include TNF-α, TNF receptor-1, and TRADD. Furthermore, Embelin makes TRAIL-mediated apoptosis more effective in cancer cells by lowering the measures of proteins that are hostile to apoptosis. These proteins include survivin, Bcl-2, and c-FLIP, among others [27].

Embelin serves as an impetus for the enactment of the innate apoptosis pathway, which is mediated by mitochondria. In this pathway, several improvements cause the insertion of proteins belonging to the Bcl-2 family into the mitochondrial membrane. This, thus, causes the release of cytochrome C and the arrangement of the apoptosome complex, which at last leads to the initiation of caspase and the death of the cell. Embelin is

responsible for initiating apoptosis through the mitochondria-dependent pathway. It does this by hindering the development of apoptotic proteins like XIAP and accelerating the release of cytochrome C [28].

Research has been conducted to investigate the synergistic effects of Embelin in conjunction with other apoptosis-actuating drugs, such as Path, in the process of sensitising cancer cells to undergo apoptosis. It has been demonstrated that combining Embelin with TRAIL therapy can improve caspase enactment and increase the likelihood that cancer cells will undergo apoptosis [29].

Embelin's potential as a therapeutic agent for the treatment of cancer is highlighted by the way that it can activate different pathways that are involved in the process of apoptosis. Embelin might be used in the development of innovative anticancer medicines assuming extra review is conducted into its mechanisms of action and improvements are made to delivery techniques. Further research genuinely should be conducted to determine the therapeutic potential of Embelin, which is a promising ordinary chemical that offers enormous promise for the treatment of cancer [30].




**Figure 3:** Embelin causes cancer cells to undergo apoptosis via both intrinsic and extrinsic mechanisms.

**Cell cycle arrest:**

Keeping up with cellular homeostasis and guaranteeing the proper transmission of genetic data depend heavily on the cell cycle, a firmly controlled process that controls cell development and division. Cancer is indicated by dysregulation of the cell cycle, wherein cells frequently proliferate wildly. As a result, zeroing in on the cell cycle has become a viable cancer treatment approach. Embelin, a distinctive substance from the Embelia genus, has demonstrated enormous promise in changing the cell cycle and impeding the development of cancer cells [31].

DNA synthesis (S), G2 (hole 2), M (mitosis), G0 (quiescent phase), and G1 (hole 1) are the five unmistakable phases that make up the cell cycle. Before continuing on toward further stages, fundamental checkpoints like G1/S and G2/M verify the exactness of DNA synthesis and examine cellular integrity. These checkpoints can be dysregulated, which can cause strange cell cycle progression and help in the development of growths [32].

Research has indicated that Embelin represses the development of cancer cells by prompting cell cycle arrest in several stages of the cancer cell life cycle. For instance, treatment with Embelin caused a huge G0/G1 phase arrest in cerebrum glioma cells (U87 cells). The expression of significant regulatory proteins required for the advancement of the G1 phase, including as CDK4, CDK6, and cyclin D1, decreased concurrently with this [33].

Embelin was discovered to connect with mortalin, a heat shock chaperone protein that is overexpressed in cancer cells, in human breast cancer cells (MCF-7 and MDA-MB-231). Through this connection, the development suppressor protein p53 was activated, which resulted in cell division restraint and G1 phase arrest [34].

Embelin-induced cell cycle arrest at the G2/M phase in osteosarcoma cells (MG63 cells and U-2 operating system) has been documented in research. A molecular examination demonstrated a decrease in the protein expressions of

fundamental regulators of G2/M phase progression, namely CDK1, cyclin B1, CDK2, CDC25B, and CDC25C [35].

Embelin caused cell cycle arrest in gastric cancer cells in both the S and G2/M stages. Downregulation of significant cell cycle regulatory proteins, like CDK1, cyclin B1, CDK2, CDC25B, and CDC25C, was linked to this effect [36].

Embelin's capacity to alter several cell cycle checkpoints features its promise as areas of strength for an agent for the treatment of cancer. Embelin shows considerable promise for the development of innovative anticancer medicines by instigating cell cycle arrest and suppressing the proliferation of cancer cells. To completely realize its therapeutic potential in clinical settings, more investigation into its mechanisms of activity and improvement of organization techniques are necessary [37].




**Figure 4:** Cell cycle arrest is induced by embelin at various periods**.**

**Autophagy:**

Autophagy, a cellular mechanism essential for keeping up with homeostasis and removing damaged proteins and organelles, assumes a double part in the development and hindrance of cancer. Cells activate autophagy as an endurance mechanism to deal with stressful circumstances like organelle interruption or food restriction and keep up with cellular integrity. Autophagosomes, which are double-membrane vesicles that engulf and transfer cytoplasmic contents to lysosomes for breakdown and recycling, are developed during this process. Autophagy-related proteins (ATGs) are among the complex proteins that assume a vital part in the orchestration of autophagy. These proteins combine hierarchically to create pre-autophagosomal structures (PAS) and promote autophagosome development [38].

Embelin is a unique molecule that shows promise as a therapeutic agent. It has been displayed to trigger autophagy in numerous cancer cell types. Treatment with Embelin caused the human tongue squamous cells (Ca9-22 cells) to convert from LC3-I to LC3-II, showing the implementation of autophagy. Moreover, it was observed that autophagy-associated proteins like the Beclin-1, p62/SQSTM1, and ATG5-ATG12 complex were degraded, showing an increased autophagic progress. Embelin essentially activated autophagy in ovarian cancer cell lines, as seen by the aggregation of Beclin-1 and GFP-LC3 proteins, affirming its capability in accepting autophagy.

Embelin's change of autophagy offers a promising new therapeutic methodology for the treatment of cancer. By advancing autophagy, Embelin might have development suppressive effects by aiding the removal of harmed cellular components and restricting the increase of cancer cells. Furthermore, by supporting cellular stress and accelerating apoptotic cell death, Embelin's acceptance of autophagy may make cancer cells more susceptible to other therapeutic interventions, like chemotherapy or targeted therapy.

Explaining the molecular pathways behind Embelin-induced autophagy and its suggestions for cancer treatment is pivotal. Comprehending the complex interactions between autophagy and other natural mechanisms, including as cell cycle regulation and apoptosis, is essential to amplifying Embelin's therapeutic potential in the treatment of cancer. Moreover, making an interpretation of these discoveries into pragmatic applications would depend on further developing medication delivery techniques to increase Embelin's bioavailability and targeting specificity. Embelin's capacity to trigger autophagy features its potential as a viable therapeutic agent for the treatment of cancer. More investigation into how it affects autophagy control and how it functions in concert with other anticancer treatments will open entryways for its clinical application and future developments in cancer treatment [39].

**Other Signal Transduction Pathways:**

Embelin is a unique substance with a variety of pharmacological effects that has attracted critical interest due to its potential use as a cancer treatment agent. Numerous development restraining mechanisms of Embelin have been completely studied, including its capacity to alter significant sign transduction pathways implicated in the pathophysiology of cancer. The Nuclear Variable kB (NF-κB) pathway is especially significant among these pathways since it is essential for immunological response, cell endurance, and irritation.

The NF-κB pathway is activated in response to several improvements, for example, provocative mediators, development factors, and oncogenic stress. When activated, NF-κB moves into the nucleus and controls the expression of genes related to aggravation, apoptosis, and cell development. Research has indicated that Embelin capabilities as an inhibitor of the NF-κB pathway, which thus restrains the advancement of development. By restraining NF-κB actuation, Embelin causes apoptosis in glioma cells, which suppresses cell division and attack. Embelin represses development by pursuing other flagging pathways, for example, the Akt pathway, that are linked to the advancement of cancer. The serine/threonine kinase Akt assumes a basic part in cell endurance and proliferation. Embelin represses the Akt hailing pathway in a variety of cancer cell types, including prostate cancer cells, which causes apoptosis and lowers the practicality of the cells. Moreover, Embelin hinders the development of cancer cells by controlling the movement of mortalin, which triggers the initiation of the cancer suppressor gene p53.

Embelin has demonstrated its capacity to upset the interleukin-6/STAT3 hailing pathway, which is connected to the etiology of colorectal cancer and incendiary bowel illness. Embelin hinders JAK2 and c-Src inception, which restrains STAT3 movement and results in the downregulation of STAT3 protein creation. Consequently, this triggers caspase-3 enactment and death, which thus suppresses the development of cancer cells.

Embelin's diverse development hindering activities, which are mediated by changes to significant flagging pathways like Akt, NF-κB, and STAT3, feature the medication's promise as a promising treatment for cancer. For Embelin's clinical development and future prospects in cancer therapy, more investigation is necessary to explain the molecular mechanisms behind its effects and improve its therapeutic efficacy [40].

**Table 3: Mechanisms of Embelin in Anticancer Activity**

| Anticancer effects | Mechanisms | Molecular and cellular targets | References |
|---|---|---|---|
| Apoptosis induction | Embelin triggers programmed cell death in cancer cells, vital for controlling growth development. | - Inherent Pathway: Involves mitochondrial processes with Bcl-2 family proteins (XIAP, Mcl-1, BclxL, Bcl-2, Smac, Bak, Bid, Bax), cytochrome C, apoptosome (caspase-9, cytochrome C, Apaf1). - Extrinsic Pathway: Death receptor-mediated, including TNF, Fas-L, TRAIL, DR4/DR5, c-FLIP, survivin, Bcl-2. | Morana (2022) Das (2021) Pfeffer(2018) Elmore (2007) Jiang (2013) Siegelin (2009) Hu (2015) Liang (2021) Jan and Chaudhry, (2019) Kim, 2005; Ghobrial ( 2005) Park (2015) |

| | | | |
|---|---|---|---|
| Cell cycle arrest | Embelin disrupts the cell cycle in cancer cells, preventing uncontrolled division. | - Involves CDK4, CDK6, cyclin D1, p53, CDK1, cyclin B1, CDK2, CDC25B, and CDC25C, leading to arrest in G0/G1 and G2/M phases. | Wang (2013)<br>Nigam (2015)<br>Qian (2018) |
| Autophagy | Embelin induces autophagy, a cellular degradation process, in cancer cells. | - Involves LC3-I/II, ATG5-ATG12 complex, p62/SQSTM1, Beclin-1, ULK1/Atg1 complex, PI3K, VDAC1 in the arrangement of autophagosomes and autophagolysosomes. | Lee (2017)<br>Jehan (2012)<br>Poojari (2014)<br>Russell (2014)<br>Yun and Lee, (2018)<br>Onorati (2018)<br>Cao (2021)<br>Li (2020)<br>Yang (2021) |
| Signal transduction modulation | Embelin affects key pathways involved in cancer pathophysiology. | - NF-κB Pathway: Involves restraint and transcriptional regulation. - PI3K/Akt Pathway: Suppresses XIAP, leading to apoptosis. - STAT3 Flagging: Downregulates STAT3, influencing JAK2, c-Src, and prompting apoptosis. | Soubannier and Stifani, (2017)<br>Park 2(015)<br>Israël (2010)<br>Mizukami (2002) |

**Limitations:**

Even while normal bioactive combinations, such as Embelin, have a bright future as anticancer treatments, there are a number of obstacles that stand in the way of their widespread usage as critical therapeutics, making it difficult to transfer these substances from preclinical research to clinical applications. The paucity of clinical data demonstrating their safety and effectiveness in cancer patients poses a major obstacle. Although preclinical research has indicated their anticancer properties, comprehensive clinical preliminary studies are required to prove their efficacy, ascertain the optimal dosages, and assess long-term safety.

The bioavailability and pharmacokinetics of typical bioactive combinations present another fundamental challenge. Many of these mixes have poor tissue penetration, poor bioavailability, and restricted solvency, all of which can reduce their therapeutic effectiveness. For example, the restricted water dissolvability of Embelin has hindered its therapeutic application. Nonetheless, ongoing attempts are made to increase its solvency through fundamental modifications and plan enhancements.

Additional issues come with quality control and normalisation. Typical bioactive blends come from a variety of sources, which causes differences in their molecular structure. It is difficult to guarantee constant potency, effectiveness, and quality across batches, necessitating stringent quality control procedures.

Concerns about drug resistance and unfavourable side effects are also present since regular bioactive combinations, such as traditional chemotherapeutic treatments, may encounter these issues. Creating plans to reduce toxicity and get around drug resistance is crucial to their successful clinical use. Important obstacles are posed by commercialization and regulatory issues. Developing and commercialising standard bioactive combinations is discouraged by restricted market exclusivity and complex regulatory environments. Collaboration between researchers, clinicians, regulatory bodies, and pharmaceutical corporations is necessary to overcome these obstacles. Even while regular bioactive mixes, like Embelin, have potential as anticancer treatments, overcoming the many obstacles they confront is crucial to successfully integrating them into clinical practice. For them to reach their full potential and benefit cancer patients, more investigation, preliminary clinical data, and creative thinking are required.

**Conclusions And Future Perspectives:**

Embelin is a naturally occurring bioactive molecule that has gained a lot of attention lately because of its possible use in cancer treatment. This resurgence of interest is a result of growing awareness of its therapeutic benefits and the need for further thorough investigation of its clinical uses. The goal of the current review is to close the gap between laboratory research and practical clinical application by delving deeper into Embelin's anticancer effects. Numerous ways that Embelin fights cancer have been revealed by studies of the drug. It can be used to relieve irritation, promote programmed cell death (apoptosis), inhibit angiogenesis and metastasis, and inhibit cell growth. Embelin's promise as a versatile therapeutic agent against cancer is highlighted by its ability to affect many pathways, such as PI3K/Akt, STAT3, and NF-κB. These pathways play a pivotal role in propelling various facets of cancer development, encompassing growth and resilience, as well as invasion and dissemination. There are a number of issues with the clinical interpretation of Embelin that need to be resolved. Improving its bioavailability is a major obstacle to successful delivery to the intended tissues. Moreover, improving delivery and detailed methods is crucial to maximising Embelin's therapeutic benefit and minimising any possible negative effects. The

first steps in advancing Embelin towards clinical use include also figuring out the right dosages and assessing safety profiles in clinical settings.

To affirm Embelin's safety and effectiveness in people, carefully planned clinical preliminary studies are essential. These preliminary discoveries would major areas of strength for offer of Embelin's anticancer properties and explain whether it very well might be used as a stand-alone treatment or related to more conventional therapies. Also, research ought to zero in on finding biomarkers and patient selection standards so that tailored treatment plans might be implemented. By expecting and observing the response to Embelin treatment, this customized approach can improve therapeutic outcomes while addressing both efficacy and safety. Studies on the toxicity of Embelin have yielded encouraging results about its safety profile; in creature models, certain dosages have not been displayed to have any huge negative effects. However, differences in results feature the need for more research and improvement. Despite these difficulties, preclinical research has shown that Embelin affects a variety of cancer cell lines, giving a strong groundwork to its clinical interpretation. There is a ton of potential for clinical applications in the investigation of Embelin as an anticancer medication. Pushing ahead, in-depth research is essential to opening its maximum capacity, including carefully planned clinical preliminary studies. In the event that Embelin can overcome the challenges related to its clinical interpretation, it can possibly become a valuable expansion to the arsenal of anticancer medicines, giving cancer patients renewed hope and better outcomes.

**References:**


[1] *Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks the nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol. 2007;71:209-19. doi: 10.1124/mol.106.028787.*

[2] *Alam MS, Damanhouri ZA, Ahmad A, Abidin L, Amir M, Aqil M, et al. Development of response surface methodology for optimization of extraction parameters and quantitative estimation of embelin from Embelia ribes Burm by high performance liquid chromatography. Pharmacogn Mag. 2015;11(Suppl 1):S166-72. doi: 10.4103/0973-1296.157722.*

[3] *Alimbetov D, Askarova S, Umbayev B, Davis T, Kipling D. Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells. Int J Mol Sci. 2018; 19(6):1690. doi: 10.3390/ijms19061690.*

[4] *B A, Fernandez A, Laila SP, Nair AS, Vishnu VS. Synthesis, characterization, molecular docking and anticancer studies of fluoroaniline derivatives of hydroxybenzoquinone and hydroxynaphthoquinone. J Biomol Struct Dyn. 2022;40:3917-27. doi: 10.1080/07391102.2020.1852116.*

[5] *Basha NJ, Basavarajaiah SM, Baskaran S, Kumar P. A comprehensive insight on the biological potential of embelin and its derivatives. Nat Prod Res. 2022;36: 3054-68. doi: 10.1080/14786419.2021.1955361.*

[6] *Cao W, Li J, Yang K, Cao D. An overview of autophagy: Mechanism, regulation and research progress. Bull Cancer. 2021;108:304-22. doi: 10.1016/j.bulcan.2020.11.004.*

[7] *Chen J, Nikolovska-Coleska Z, Wang G, Qiu S, Wang S. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg Med Chem Lett. 2006; 16:5805–8. doi: 10.1016/j.bmcl.2006.08.072.*

[8] *Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, et al. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res. 2009;69:4776-83. doi: 10.1158/0008-5472.CAN-08-4754.*

[9] *Dai Y, Desano J, Qu Y, Tang W, Meng Y, Lawrence TS, et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res. 2011;1:128-43.*

[10] *Dai Y, Jiao H, Teng G, Wang W, Zhang R, Wang Y, et al. Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. Mol Cancer Ther. 2014;13:1206-16. doi: 10.1158/1535- 7163.MCT-13-0378.*

[11] *Danquah M, Li F, Duke CB 3rd, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res. 2009;26:2081-92. doi: 10.1007/s11095-009-9903-5.*

[12] *Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Pharm Res. 2012;29:2079-91. doi: 10.1007/s11095-012- 0737-1.*

[13] Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021;26:512-33. doi: 10.1007/s10495-021-01687-9.

[14] Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366. doi: 10.1177/20503121211034366.

[15] Dhanjal JK, Nigam N, Sharma S, Chaudhary A, Kaul SC, Grover A, et al. Embelin inhibits TNF-α converting enzyme and cancer cell metastasis: molecular dynamics and experimental evidence. BMC Cancer. 2014;14:775. doi: 10.1186/1471-2407-14-775.

[16] Durg S, Veerapur VP, Neelima S, Dhadde SB. Antidiabetic activity of Embelia ribes, embelin and its derivatives: A systematic review and meta-analysis. Biomed Pharmacother. 2017;86:195-204. doi: 10.1016/j.biopha.2016.12.001.

[17] Edderkaoui M, Lugea A, Hui H, Eibl G, Lu QY, Moro A, et al. Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells. Nutr Cancer. 2013;65:1232-44. doi: 10.1080/01635581.2013.832779.

[18] Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516. doi: 10.1080/01926230701320337.

[19] Elwakeel A. Abrogating the interaction between p53 and mortalin (Grp75/HSPA9/mtHsp70) for cancer therapy: the story so far. Front Cell Dev Biol. 2022;10: 879632. doi: 10.3389/fcell.2022.879632.

[20] EU, European Commission. EU-funded projects for a cancer-free Europe! https://hadea.ec.europa.eu/news/eu-funded-projects-cancer-free-europe2022-01-31_en. 2023.

[21] Fu X, Pang X, Qi H, Chen S, Li Y, Tan W. XIAP inhibitor Embelin inhibits bladder cancer survival and invasion in vitro. Clin Transl Oncol. 2016;18:277-82. doi: 10.1007/s12094-015-1363-2

[22] Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-94. doi: 10.3322/canjclin.55.3.178. Government of India, Ministry of Health & Family Welfare: National programme for prevention & control of cancer, diabetes, cardiovascular diseases & stroke (NPCDCS). India, 2023. https://nhm.gov.in/index1.php?lang=1&level=2&sublinkid=1048&lid=604

[23] Gupta S, Sanyal SN. Biodistribution of embelin, a benzoquinone of male antifertility potential. Fitoterapia. 1991;62:419-24.

[24] Heo JY, Kim HJ, Kim SM, Park KR, Park SY, Kim SW, et al. Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN. Cancer Lett. 2011; 308(1):71-80. doi: 10.1016/j.canlet.2011.04.015.

[25] Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H, et al. Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol. 2011;28: 1584-8. doi: 10.1007/s12032-010-9601-5.

[26] Hu R, Yang Y, Liu Z, Jiang H, Zhu K, Li J, et al. The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation. Tumour Biol. 2015;36:769-77. doi: 10.1007/s13277-014-2702-6.

[27] Huang J, Ngai CH, Deng Y, Tin MS, Lok V, Zhang L, et al. Cancer incidence and mortality in Asian countries: a trend analysis. Cancer Control. 2022;29:10732748221095955. doi: 10.1177/10732748221095955.

[28] Huang M, Tang SN, Upadhyay G, Marsh JL, Jackman CP, Shankar S, et al. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways. PLoS One. 2014;9(4):e92161. doi: 10.1371/journal.pone.0092161.

[29] Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, et al. XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer. 2017;17(1):640. doi: 10.1186/s12885-017-3627-4.

[30] Israël A. The IKK complex, a central regulator of NFkappaB activation. Cold Spring Harb Perspect Biol. 2010;2(3):a000158. doi: 10.1101/cshperspect.a000158.

[31] Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9:205-18. doi: 10.15171/apb.2019.024.

[32] Jehan Z, Al-obaisi KA, Uddin S, Al-Kuraya K. Embelin induces autophagy in ovarian cancer cells. Cancer Res. 2012;72(8_Suppl):2265.

[33] Jiang L, Hao JL, Jin ML, Zhang YG, Wei P. Effect of Embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev. 2013;14:6115-20. doi: 10.7314/apjcp.2013.14.10.6115.

[34] Kamble V, Attar U, Umdale S, Nimbalkar M, Ghane S, Gaikwad N. Phytochemical analysis, antioxidant activities and optimized extraction of embelin from different genotypes of Embelia ribes Burm f.: a woody medicinal climber from Western Ghats of India. Physiol Mol Biol Plants. 2020;26:1855-65. doi: 10.1007/s12298-020-00859-2.

[35] Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005;103:1551-60. doi: 10.1002/cncr.20947.

[36] Ko JH, Lee SG, Yang WM, Um JY, Sethi G, Mishra S, et al. The application of embelin for cancer prevention and therapy. Molecules. 2018;23(3):621. doi: 10.3390/molecules23030621.

[37] Kocaturk NM, Akkoc Y, Kig C, Bayraktar O, Gozuacik D, Kutlu O. Autophagy as a molecular target for cancer treatment. Eur J Pharm Sci. 2019;134:116-37. doi: 10.1016/j.ejps.2019.04.011.

[38] Kundap UP, Bhuvanendran S, Kumari Y, Othman I, Shaikh MF. Plant derived phytocompound, embelin in cns disorders: a systematic review. Front Pharmacol. 2017;8:76. doi: 10.3389/fphar.2017.00076.

[39] Lee YJ, Park BS, Park HR, Yu SB, Kang HM, Kim IR. XIAP inhibitor embelin induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells. Environ Toxicol. 2017;32:2371-8. doi: 10.1002/tox.22450.

[40] Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12. doi: 10.1186/s12943-020-1138-4.

*****